Spaceflight and hindlimb suspension disuse models in mice.
Osteoporosis is a disease characterized by low bone mass and structural deterioration of bone tissue, leading to bone fragility and increased susceptibility to fractures. The microgravity of space creates an extreme environment that provides a model for osteoporosis in humans. This greatly accelerated form of osteopenia results in a 0.5-2% loss of bone mass per month. Rat models for this osteoporosis have been examined on many occasions, but STS-108 was the first Space Shuttle flight to use mice. Data reported to date indicate that spaceflight experiments with mice hold promise in predicting some spaceflight effects on humans. Due to the cost and infrequency of flights, ground-based models have been developed to mimic the deleterious effects of the microgravity environment. Hindlimb suspension is one such localized model. This model removes gravitational loading from the hindlimbs by suspending the animal by its tail to a guy wire that runs lengthwise across the cage. Because mice had not flown before STS-108, a direct comparison of this model's ability to predict spaceflight results has not been examined. The objective of this research is to closely repeat the STS-108 profile, with hindlimb suspension replacing spaceflight. This includes examining the ability of the protein osteoprotegerin, an osteoclast-inhibiting therapeutic, to mitigate the deleterious effects of skeletal unloading. It is expected that the results will lead to better understanding of the mechanisms of mineralization and bone remodeling to aid in development of countermeasures to prevent spaceflight induced osteoporosis and aid the treatment of osteoporosis here on earth.
Milstead
Jeffery R
JR
Clemson University, Department of Bioengineering, Clemson, SC 29634, USA.
Simske
Steven J
SJ
Bateman
Ted A
TA
D000818:Animals; D001835:Body Weight; D015519:Bone Density; D005269:Femur / Q000187:drug effects / Q000473:pathology* / Q000503:physiopathology*; D006023:Glycoproteins / Q000627:therapeutic use; D006614:Hindlimb / Q000187:drug effects / Q000473:pathology / Q000503:physiopathology; D019417:Hindlimb Suspension / Q000502:physiology*; D051379:Mice; D008810:Mice, Inbred C57BL; D020966:Muscular Disorders, Atrophic / Q000209:etiology / Q000473:pathology* / Q000503:physiopathology* / Q000517:prevention & control; D053244:Osteoprotegerin; D018160:Receptors, Cytoplasmic and Nuclear / Q000627:therapeutic use; D018124:Receptors, Tumor Necrosis Factor; D013026:Space Flight; D014893:Weightlessness / Q000009:adverse effects*; D018474:Weightlessness Simulation / Q000009:adverse effects
D006023:Glycoproteins; D053244:Osteoprotegerin; D018160:Receptors, Cytoplasmic and Nuclear; D018124:Receptors, Tumor Necrosis Factor; C506031:Tnfrsf11b protein, mouse; C506032:Tnfrsf11b protein, rat